My pleasure to host rising starts in Penn Medicine - Abramson Cancer Center Heme/Onc Fellowship for journal club reviewing AGILE Ivo/aza manuscript!

Happy to share the LTFU data from VIALE-A Phase III trial for Newly diagnosed AML unfit for induction. With 43.2 months follow up median OS 14.7m with Venetoclax/Azacitidine. Details of dosing adjustments in patients on therapy >6 cycles included. onlinelibrary.wiley.com/doi/10.1002/aj…

Thank you for including me in this great exchange of knowledge among experts across the globe!

It was my honor to meet with Dr Figaro and his team at Méderi Hospital in Bogota Colombia this morning to discuss the rapidly changing treatments for AML. Amazing to see our colleagues home hospital and exchange experiences treating our patients. Thank you.

Just felt Philadelphia earthquake here in center city M 4.8 - 5 km NE of Lebanon, New Jersey earthquake.usgs.gov/earthquakes/ev…

Not often that we see cyclophosphamide and haploidentical hematopoietic cell transplantation as the focus of a feature article in a mainstream magazine. Nice write-up in The Atlantic: CIBMTR ASH theatlantic.com/health/archive…

Back in Baltimore and grateful to present at Johns Hopkins Oncology Grand rounds on the evolution of AML therapy in the Modern Targeted Era

Happy to share our paper describing the benefit in addition of Blinatumomab in Newly diagnosed MRD negative B cell ALL. Congratulations to all who were part of this cooperative effort! nejm.org/doi/full/10.10…

Happy to share novel risk signature for AML treated with Azacitidine and Venetoclax. These data derived from VIALE-A trial demonstrate mutations in four genes (TP53, FLT-3, KRAS, & NRAS) predict patient outcomes more definitively than ELN2022 or ELN 2017. doi.org/10.1182/blood.…

Thank you Brittany, and thank you for including me in your great meeting! It was a great debate!

The UPENN Leukemia Program is recruiting clinicians for the 2025 academic year in Philadelphia. The leukemia team consists of a group of global leaders in their fields with track records for successful mentorship. If interested please apply at apply.interfolio.com/157257

Happy to share our report on the utility of post remission use of GCSF in the VIALE-A trial. In the CR/CRi patients given GCSF, OS was 30.8 m vs 21.1 mo and MRD neg response 51% vs 33%. Important data to feel safe to use GCSF w/ blast clearance. onlinelibrary.wiley.com/doi/10.1002/aj…

“The needs of the patient come first” 1910 Dr William J Mayo. Thank all the professionals and institutions who aspire to this, particularly those who sacrifice time away from family this time of year.

Last day of Leukemia service after an amazing two week rotation with Dr Maleeha Ahmad, Dr Ryan Chow, Dr Eamonn Brace and Dr Lukas Ronner. Humbled by the group coordinated attire and thank the team for their great clinical care and eagerness to learn Leukemia.

Gracias por invitarme a tu gran conferencia. ¡Fue un honor compartir nuestro trabajo sobre nuevas terapias para LMA!

Happy to share my review on Incorporating Molecularly Targeted therapy in frontline therapy for fit patients with AML. With Dr Harry Erba onlinelibrary.wiley.com/doi/10.1002/aj…

Thank you Roberta, for the invitation to review our progress in AML therapy. I also want to thank your colleagues for the thoughtful discussion of complex leukemia cases throughout my visit. I hope we can continue to learn from each other how best to care for our patients!

Search for novel strategies in TP53 AML reveals mevalonate pathway importance in chemoreststance. Congratulations to Sarah Skuli and team on this work!